Toggle Nav
My Cart
Search
Advanced Search
Menu
Account
Settings

Global Decentralized Clinical Trials Growth Opportunities

Global Decentralized Clinical Trials Growth Opportunities

Strong Competitive Intensity is Advancing DCT Initiatives Across the World Paving Way for a Partnership-based Growth Model

RELEASE DATE
15-Sep-2023
REGION
North America
Deliverable Type
Market Research
Research Code: PF10-01-00-00-00
SKU: HC_2023_142
AvailableYesPDF Download
$4,950.00
In stock
SKU
HC_2023_142

Global Decentralized Clinical Trials Growth Opportunities
Published on: 15-Sep-2023 | SKU: HC_2023_142

Need more details?
$4,950.00
DownloadLink
Request Sample
Add to Compare
Need more details?
Description

The global decentralized clinical trial (DCT) market has been witnessing a continued surge after the COVID-19 pandemic. The accelerated DCT adoption in 2020 was driven by restricted mobility of site investigators, clinical research associates, and patients to participate in trials, which resulted in a significant halt in trial activities worldwide. To ensure patient safety and continuity in the R&D activities, most sponsors and contract research organizations (CROs) adopted digital tools to support trial operations, including telemedicine, remote source data verification, and sensor/mobile technology-enabled direct data-capture solutions.

Regulatory agencies around the world are coming up with initiatives and guidelines for large-scale adoption of DCT modalities, alongside existing alliances, such as Decentralized Trials & Research Alliance (DTRA), that work toward increasing DCT awareness, propelling remote trial uptake.

North America continues to lead the DCT market owing to a strong presence of DCT vendors, CROs, and pharma sponsors in the region, followed closely by Europe, which has abundant infrastructure for large-scale DCT uptake. Nevertheless, Asia-Pacific is emerging as a crucial region with several leading global CROs establishing strong bases due to patient diversity, treatment-naive population, and significant cost advantage. In addition, there is a growing reliance on telemedicine and ePharmacy solutions in the region, which will propel DCT uptake in 3 to 5 years. In the Rest of World region, the Middle East is gearing up for greater remote trial adoption, with Kingdom of Saudi Arabia and Dubai at the forefront. Several tech vendors, such as Oracle and AWS, have set up bases in the region to allow the uptake of eClinical solutions, promoting growth. However, at present, the market will have comparatively slower growth than other regions.

There will be a constant need to support decentralized trials through cloud-based platform solutions that are fit to purpose. Therefore, CROs are building decentralized trial capabilities by partnering with technology vendors. In addition, online training modules for patients and secure technology for at-home trial monitoring through devices, chatbots, and sensors have been driving the adoption of decentralized trials after the pandemic.

Home health services for patients with physical disabilities and restricted access due to location can promote retention in clinical trials. Partnering with home health service providers supported by nurses trained in portable equipment usage will facilitate smooth DCT implementation. In addition, CROs are focused on innovating trial enrollment and patient engagement strategies by exploring multiple channels, such as the use of advocacy groups, social media, and online physician referral systems, as well as implementing AI-enabled platforms, expanding the DCT ecosystem.

Author: Aarti Siddhesh Chitale

Table of Contents

Why Is It Increasingly Difficult to Grow?

The Strategic Imperative 8™

The Impact of the Top 3 Strategic Imperatives on the Decentralized Clinical Trial (DCT) Industry

Growth Opportunities Fuel the Growth Pipeline Engine™

Scope of Analysis

Decentralized Clinical Trials Market Segmentation

Growth Metrics

Comparison of Traditional and Decentralized Clinical Trials

DCT Value Proposition: Achieving Patient Centricity

Decentralized Clinical Trials: Pharma Ecosystem

Decentralized Clinical Trials: Patient Ecosystem

Market Trend Analysis

Evolving DCT Landscape

Global DCT Initiatives and Guidelines

Global DCT Initiatives and Guidelines (continued)

Global DCT Initiatives and Guidelines (continued)

Global DCT Initiatives and Guidelines (continued)

Implications of DCT Initiatives on the Global DCT Market

Implications of DCT Initiatives on Individual Stakeholders

Growth Drivers

Growth Restraints

DCT: Evolving Vendor Ecosystem

DCT: Evolving Vendor Ecosystem (continued)

DCT: Evolving Vendor Ecosystem (continued)

Business Model Trend: Global DCT Market

Partnership Trends Driving DCT Business Models

Strategic Partnerships in DCT Market

Strategic Partnerships in DCT Market (continued)

Strategic Partnerships in DCT Market (continued)

Strategic Partnerships in DCT Market (continued)

Strategic Partnerships in DCT Market (continued)

Strategic Partnerships in DCT Market (continued)

Key Mergers and Acquisitions

New Platform Launches

New Platform Launches (continued)

Forecast Assumptions

Forecast Assumptions (continued)

Revenue Forecast: Global

Revenue Forecast Analysis

Revenue Forecast Analysis (continued)

Revenue Forecast Analysis (continued)

Revenue Forecast by Phases of Clinical Development

Revenue Percentage by Phase of Development

Revenue Forecast by Clinical Development Phases

Revenue Share Analysis by Therapy Areas

Revenue Share Analysis by Therapy Areas

Revenue Share Analysis by Therapy Areas (continued)

Revenue Forecast by Regions

Revenue Forecast Analysis by Region: DCT Market

Revenue Forecast Analysis: North America

Revenue Forecast Analysis: Europe

Revenue Forecast Analysis: Asia-Pacific (APAC)

Revenue Forecast Analysis: Rest of World (RoW)

Competitive Environment

Competitor Benchmarking: Pure-play DCT Vendors

Competitor Benchmarking: CROs (Enablers/DCT Vendors)

Competitor Benchmarking: DCT Enablers

Competitor Assessment

Competitor Assessment (continued)

Growth Opportunity 1: Endpoint Assessment with Digital Biomarkers

Growth Opportunity 1: Endpoint Assessment with Digital Biomarkers (continued)

Growth Opportunity 2: Digital Health Technology (DHT)-enabled Focus on Oncology Trials

Growth Opportunity 2: Digital Health Technology (DHT)-enabled Focus on Oncology Trials (continued)

Growth Opportunity 3: Adopting Partnership-based Approaches for Scaling DCT Capabilities

Growth Opportunity 3: Adopting Partnership-based Approaches for Scaling DCT Capabilities (continued)

Your Next Steps

Why Frost, Why Now?

List of Exhibits

Legal Disclaimer

Request Sample
Purchase includes:
  • Report download
  • Growth Dialog™ with our experts
Related Research
  1. Growth Opportunities in Drug Discovery and Early Development Outsourcing Services
    $4,950.00 Release Date: 20-Feb-24
  2. Precision Neurodegenerative Disease Market, Global, 2024 2028
    $2,450.00 Release Date: 26-Aug-24
  3. Top 5 Growth Opportunities for the Pharmaceutical Industry, 2024
    $2,450.00 Release Date: 03-Jan-24
  4. Growth Opportunities in US and European Hospital Workflow Digital Platforms and Solutions in Acute Care, Forecast to 2028
    $4,950.00 Release Date: 17-May-24
  5. Pharmaceutical Commercialization Solutions and Services Industry, Global, 2024 2029
    $4,950.00 Release Date: 10-Sep-24

Growth Dialog™

A tailored session with you where we identify the:
  • Strategic Imperatives
  • Growth Opportunities
  • Best Practices
  • Companies to Action

Impacting your company's future growth potential.

The global decentralized clinical trial (DCT) market has been witnessing a continued surge after the COVID-19 pandemic. The accelerated DCT adoption in 2020 was driven by restricted mobility of site investigators, clinical research associates, and patients to participate in trials, which resulted in a significant halt in trial activities worldwide. To ensure patient safety and continuity in the R&D activities, most sponsors and contract research organizations (CROs) adopted digital tools to support trial operations, including telemedicine, remote source data verification, and sensor/mobile technology-enabled direct data-capture solutions. Regulatory agencies around the world are coming up with initiatives and guidelines for large-scale adoption of DCT modalities, alongside existing alliances, such as Decentralized Trials & Research Alliance (DTRA), that work toward increasing DCT awareness, propelling remote trial uptake. North America continues to lead the DCT market owing to a strong presence of DCT vendors, CROs, and pharma sponsors in the region, followed closely by Europe, which has abundant infrastructure for large-scale DCT uptake. Nevertheless, Asia-Pacific is emerging as a crucial region with several leading global CROs establishing strong bases due to patient diversity, treatment-naive population, and significant cost advantage. In addition, there is a growing reliance on telemedicine and ePharmacy solutions in the region, which will propel DCT uptake in 3 to 5 years. In the Rest of World region, the Middle East is gearing up for greater remote trial adoption, with Kingdom of Saudi Arabia and Dubai at the forefront. Several tech vendors, such as Oracle and AWS, have set up bases in the region to allow the uptake of eClinical solutions, promoting growth. However, at present, the market will have comparatively slower growth than other regions. There will be a constant need to support decentralized trials through cloud-based platform solutions that are fit to purpose. Therefore, CROs are building decentralized trial capabilities by partnering with technology vendors. In addition, online training modules for patients and secure technology for at-home trial monitoring through devices, chatbots, and sensors have been driving the adoption of decentralized trials after the pandemic. Home health services for patients with physical disabilities and restricted access due to location can promote retention in clinical trials. Partnering with home health service providers supported by nurses trained in portable equipment usage will facilitate smooth DCT implementation. In addition, CROs are focused on innovating trial enrollment and patient engagement strategies by exploring multiple channels, such as the use of advocacy groups, social media, and online physician referral systems, as well as implementing AI-enabled platforms, expanding the DCT ecosystem. Author: Aarti Siddhesh Chitale
More Information
Deliverable Type Market Research
Author Aarti Siddhesh Chitale
Industries Healthcare
No Index No
Is Prebook No
Keyword 1 Clinical Trial Technology
Keyword 2 Remote Patient Monitoring
Keyword 3 Clinical Trial Decentralization
Podcast No
WIP Number PF10-01-00-00-00